Cartesian Therapeutics Inc (RNAC)

01:24 AM

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.14 - Defense World

01:24 AM

Apr 02, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Apr 02, 2025

Apr 02, 2025

Cartesian Therapeutics Expands Cell Therapy Team with Strategic New Hires - Stock Titan

Apr 02, 2025

Apr 01, 2025

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Leading mRNA Cell Therapy Company Cartesian Takes Center Stage at Needham Healthcare Conference - Stock Titan

Apr 01, 2025

Apr 01, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World

Apr 01, 2025

Mar 29, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Raised by Bank of New York Mellon Corp - Defense World

Mar 29, 2025

Mar 23, 2025

Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock - Yahoo

Mar 23, 2025

Mar 20, 2025

Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock By Investing.com - Investing.com South Africa

Mar 20, 2025

Mar 20, 2025

Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock - Investing.com

Mar 20, 2025

Mar 20, 2025

Analysts Issue Forecasts for RNAC FY2025 Earnings - Defense World

Mar 20, 2025

Mar 18, 2025

Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27% - Simply Wall St

Mar 18, 2025

Mar 17, 2025

Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics By Investing.com - Investing.com Canada

Mar 17, 2025

Mar 17, 2025

Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright - Investing.com Canada

Mar 17, 2025

Mar 16, 2025

HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World

Mar 16, 2025

Mar 15, 2025

Cartesian Therapeutics' Market Cap Drops To US$430m Leaving Insiders With Losses - simplywall.st

Mar 15, 2025

Mar 15, 2025

Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World

Mar 15, 2025

Mar 14, 2025

Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer - Yahoo Finance

Mar 14, 2025

Mar 14, 2025

Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 14, 2025

Mar 14, 2025

Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger - TipRanks

Mar 14, 2025

Mar 14, 2025

Cartesian Therapeutics Advances mRNA Therapy Pipeline - TipRanks

Mar 14, 2025

Mar 13, 2025

Cartesian Therapeutics Inc. (RNAC) reports earnings - Quartz

Mar 13, 2025

Mar 13, 2025

Cartesian Therapeutics reports FY24 EPS ($4.49) vs. ($49.76) last year - TipRanks

Mar 13, 2025

Mar 13, 2025

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 13, 2025

Mar 13, 2025

Cartesian Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 13, 2025

Mar 13, 2025

Cartesian's $214M War Chest Powers Breakthrough Myasthenia Gravis Treatment into Phase 3 - StockTitan

Mar 13, 2025

Mar 11, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Bought by Rhumbline Advisers - Defense World

Mar 11, 2025

Mar 09, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Average Target Price from Analysts - Defense World

Mar 09, 2025

Mar 07, 2025

New York State Common Retirement Fund Sells 1,200 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Mar 07, 2025

Mar 06, 2025

Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times

Mar 06, 2025

Mar 06, 2025

Inside Cartesian's Latest Executive Compensation Package: Key Details Revealed - StockTitan

Mar 06, 2025

Mar 05, 2025

CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - GlobeNewswire Inc.

Mar 05, 2025

Mar 03, 2025

Cartesian Therapeutics Advances Descartes-08 in Clinical Trials - TipRanks

Mar 03, 2025

Feb 27, 2025

Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025

Feb 18, 2025

Cartesian Therapeutics to Participate in Multiple Upcoming Investor Conferences in February and March 2025 - Nasdaq

Feb 18, 2025

Feb 18, 2025

Cartesian Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Feb 18, 2025

Feb 18, 2025

Major mRNA Cell Therapy Player Sets Ambitious 3-Conference Roadshow: Key Dates Inside - Stock Titan

Feb 18, 2025

Feb 15, 2025

Mirae Asset Global Investments Co. Ltd. Has $82,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Feb 15, 2025

Feb 14, 2025

What is Leerink Partnrs' Estimate for RNAC FY2024 Earnings? - MarketBeat

Feb 14, 2025

Feb 13, 2025

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86 - MarketBeat

Feb 13, 2025

Feb 12, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Analysts - Defense World

Feb 12, 2025

Feb 11, 2025

Leerink Partnrs Issues Optimistic Estimate for RNAC Earnings - Defense World

Feb 11, 2025

Feb 09, 2025

RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Feb 09, 2025

Feb 07, 2025

What is Leerink Partnrs’ Forecast for RNAC FY2029 Earnings? - Armenian Reporter

Feb 07, 2025

Feb 06, 2025

Cartesian Therapeutics Issues Strategic Employee Stock Options Worth $3.3MInside Details - StockTitan

Feb 06, 2025